Clinical Trial Update: Remission Evaluation of a Metabolic Intervention in Type 2 Diabetes With Sitagliptin (REMIT-Sita) [Phase 3]

View source ↗

Summary

Phase 3 trial REMIT-Sita evaluates remission outcomes with a metabolic intervention plus Sitagliptin in Type 2 Diabetes; completed with results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Sitagliptin (sitagliptin)

Snippet

Sponsor: Population Health Research Institute | Conditions: Type 2 Diabetes Mellitus | Phase 3 | Status: COMPLETED | Results posted: 2022-03-14